PubMed

Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes.

Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I.

Diabetes. 2006 Mar;55(3):774-9.PMID: 16505242 [PubMed - indexed for MEDLINE]Related articlesFree article

Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control.

Cipollone F, Chiarelli F, Davì G, Ferri C, Desideri G, Fazia M, Iezzi A, Santilli F, Pini B, Cuccurullo C, Tumini S, Del Ponte A, Santucci A, Cuccurullo F, Mezzetti A.

Diabetologia. 2005 Jun;48(6):1216-24. Epub 2005 May 3.PMID: 15868137 [PubMed - indexed for MEDLINE]Related articles

Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications.

Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, Aoki T.

Diabetes. 2007 Nov;56(11):2790-6. Epub 2007 Aug 8.PMID: 17686944 [PubMed - indexed for MEDLINE]Related articlesFree article

Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation.

Devaraj S, Jialal I.

Circulation. 2000 Jul 11;102(2):191-6.PMID: 10889130 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus.

Harding SA, Sommerfield AJ, Sarma J, Twomey PJ, Newby DE, Frier BM, Fox KA.

Atherosclerosis. 2004 Oct;176(2):321-5.PMID: 15380455 [PubMed - indexed for MEDLINE]Related articles

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.

Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual AL, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U.

Circulation. 2003 Jun 3;107(21):2664-9. Epub 2003 May 12.PMID: 12742991 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy.

Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G.

Diabet Med. 2005 Aug;22(8):999-1004.PMID: 16026364 [PubMed - indexed for MEDLINE]Related articles

Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients.

Devaraj S, Jialal I.

Free Radic Biol Med. 2000 Oct 15;29(8):790-2.PMID: 11053781 [PubMed - indexed for MEDLINE]Related articles

Defining the proinflammatory phenotype using high sensitive C-reactive protein levels as the biomarker.

Devaraj S, O'Keefe G, Jialal I.

J Clin Endocrinol Metab. 2005 Aug;90(8):4549-54. Epub 2005 May 17.PMID: 15899961 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.

Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM.

Circulation. 2005 May 17;111(19):2446-53. Epub 2005 May 2.PMID: 15867184 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment.

Desfaits AC, Serri O, Renier G.

Diabetes Care. 1998 Apr;21(4):487-93.PMID: 9571329 [PubMed - indexed for MEDLINE]Related articlesFree article

Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study.

Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, Stehouwer CD; EURODIAB Prospective Complications Study.

Diabetes Care. 2003 Jul;26(7):2165-73.PMID: 12832330 [PubMed - indexed for MEDLINE]Related articlesFree article

Serum levels of interleukin 6, C-reactive protein, vascular cell adhesion molecule 1, and monocyte chemotactic protein 1 in relation to insulin resistance and glucose intolerance--the Chennai Urban Rural Epidemiology Study (CURES).

Deepa R, Velmurugan K, Arvind K, Sivaram P, Sientay C, Uday S, Mohan V.

Metabolism. 2006 Sep;55(9):1232-8.PMID: 16919544 [PubMed - indexed for MEDLINE]Related articles

Evidence that C-reactive protein or IL-6 are not surrogates for all inflammatory cardiovascular risk factors in hemodialysis patients.

Kaysen GA, Levin NW, Mitch WE, Chapman AL, Kubala L, Eiserich JP.

Blood Purif. 2006;24(5-6):508-16. Epub 2006 Oct 23.PMID: 17077623 [PubMed - indexed for MEDLINE]Related articles

Circulating interleukin-6 and high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise healthy subjects.

Marcaccini AM, Meschiari CA, Sorgi CA, Saraiva MC, de Souza AM, Faccioli LH, Tanus-Santos JE, Novaes AB, Gerlach RF.

J Periodontol. 2009 Apr;80(4):594-602.PMID: 19335079 [PubMed - indexed for MEDLINE]Related articles

Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic inflammation.

Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallén NH.

Diabetologia. 2004 Mar;47(3):537-40. Epub 2004 Feb 13.PMID: 14963650 [PubMed - indexed for MEDLINE]Related articles

Increased levels of atherosclerosis markers in salt-sensitive hypertension.

Larrousse M, Bragulat E, Segarra M, Sierra C, Coca A, de La Sierra A.

Am J Hypertens. 2006 Jan;19(1):87-93.PMID: 16461197 [PubMed - indexed for MEDLINE]Related articles

Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.

Tan KT, Tayebjee MH, Lim HS, Lip GY.

Diabet Med. 2005 Dec;22(12):1657-62.PMID: 16401308 [PubMed - indexed for MEDLINE]Related articles

Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes.

Jialal I, Miguelino E, Griffen SC, Devaraj S.

J Clin Endocrinol Metab. 2007 Aug;92(8):3136-40. Epub 2007 May 22.PMID: 17519305 [PubMed - indexed for MEDLINE]Related articlesFree article

The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein.

Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A.

Thromb Res. 2007;119(1):79-84. Epub 2006 Feb 14.PMID: 16476470 [PubMed - indexed for MEDLINE]Related articles